Drug intelligence / Profile preview

benefilgrastim

Development stage: Unknown
Lead developer: Evive Biotech
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Benefilgrastim is a recombinant human granulocyte colony-stimulating factor (rhG-CSF) dimer, specifically an rhG-CSF-FC fusion protein. It is being developed as a once-per-cycle therapy for prophylactic neutrophil support in patients receiving myelotoxic chemotherapy. The drug aims to manage severe neutropenia, a common side effect of chemotherapy, by stimulating the production of neutrophils. It was developed by Generon (Shanghai) Corporation Ltd.

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)

Beyond the preview

Go deeper on benefilgrastim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on benefilgrastim.

Explore the full profile